These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36782152)

  • 1. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
    Stiefel R; Lehmann K; Winder T; Siebenhüner AR
    BMC Cancer; 2023 Feb; 23(1):148. PubMed ID: 36782152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas.
    Russo A; DiPeri T; Dumitra T; Tseng J; Pletcher E; Justo M; Chen C; Nissen N; Amersi F; Gong J; Hendifar A; Gangi A
    J Neuroendocrinol; 2024 Aug; 36(8):e13399. PubMed ID: 38760997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.
    Ni K; Yang JY; Baeg K; Leiter AC; Mhango G; Gallagher EJ; Wisnivesky JP; Kim MK
    Cancer Rep (Hoboken); 2021 Oct; 4(5):e1387. PubMed ID: 33835729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
    Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
    Xu JX; Wu DH; Ying LW; Hu HG
    World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: a population-based study.
    Li X; Fan Y; Tong J; Lou M
    Front Endocrinol (Lausanne); 2024; 15():1264952. PubMed ID: 38449852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus.
    Thapi S; Baeg K; Kim MK; Gallagher EJ
    Pancreas; 2021 Oct; 50(9):1293-1297. PubMed ID: 34860814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
    BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiological features of gastroenteropancreatic neuroendocrine tumors in Chengdu city with a population of 14 million based on data from a single institution.
    Guo LJ; Wang CH; Tang CW
    Asia Pac J Clin Oncol; 2016 Sep; 12(3):284-8. PubMed ID: 27170574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of surgery and survival prediction in patients with gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z; Wang W; Zhang K; Fan M; Lin R
    Int J Surg; 2023 Jun; 109(6):1629-1638. PubMed ID: 37133986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
    Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
    Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
    Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
    J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper.
    Natalicchio A; Faggiano A; Zatelli MC; Argentiero A; D'Oronzo S; Marrano N; Beretta GD; Acquati S; Adinolfi V; Di Bartolo P; Danesi R; Ferrari P; Gori S; Morviducci L; Russo A; Tuveri E; Montagnani M; Gallo M; Silvestris N; Giorgino F
    Crit Rev Oncol Hematol; 2022 Jan; 169():103572. PubMed ID: 34954047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
    Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
    Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.
    Chen JS; Bai LY; Cheng HH; Chan SL; Zou JY; Shi X; Houchard A; Truong-Thanh XM; Chen MH
    Oncol Ther; 2024 Aug; ():. PubMed ID: 39215958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.